Vascular Medicine

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dayal, S.
Right arrow Articles by Lentz, S. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dayal, S.
Right arrow Articles by Lentz, S. R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Vascular Medicine, Vol. 10, No. 2 suppl, S27-S33 (2005)
DOI: 10.1191/1358863x05vm599oa

ADMA and hyperhomocysteinemia

Sanjana Dayal

Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA

Steven R Lentz

Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA, Veterans Affairs Medical Center, Iowa City, Iowa, USA, steven-lentz{at}uiowa.edu

Hyperhomocysteinemia is a risk factor for cardiovascular disease and stroke. Like many other cardiovascular risk factors, hyperhomocysteinemia produces endothelial dysfunction due to impaired bioavailability of endothelium-derived nitric oxide (NO). The molecular mechanisms responsible for decreased NO bioavailability in hyperhomocysteinemia are incompletely understood, but emerging evidence suggests that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, may be a key mediator. Homocysteine is produced during the synthesis of ADMA and can alter ADMA metabolism by inhibiting dimethylarginine dimethylaminohydrolase (DDAH). Several animal and clinical studies have demonstrated a strong association between plasma total homocysteine, plasma ADMA, and endothelial dysfunction. These observations suggest a model in which elevation of ADMA may be a unifying mechanism for endothelial dysfunction during hyper-homocysteinemia. The recent development of transgenic mice with altered ADMA metabolism should provide further mechanistic insights into the role of ADMA in hyperhomocysteinemia.

Key Words: arginine • endothelium • homocysteine • methylation • nitric oxide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. C. Looft-Wilson, B. S. Ashley, J. E. Billig, M. R. Wolfert, L. A. Ambrecht, and S. E. Bearden
Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R59 - R66.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Hong and W. Fast
Inhibition of Human Dimethylarginine Dimethylaminohydrolase-1 by S-Nitroso-L-homocysteine and Hydrogen Peroxide: ANALYSIS, QUANTIFICATION, AND IMPLICATIONS FOR HYPERHOMOCYSTEINEMIA
J. Biol. Chem., November 30, 2007; 282(48): 34684 - 34692.
[Abstract] [Full Text] [PDF]